SCHEMBL19902322

SCHEMBL19902322

CC(C)(C)OC(=O)NC1CCC(O)(c2n[nH]c(=O)c3ccccc23)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.43
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
EPHX2 P34913 1/20 0.42
JAK2 O60674 3/20 0.40
JAK1 P23458 3/20 0.40
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
PIM1 P11309 1/20 0.40
PIM3 Q86V86 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
CKS1B P61024 1/20 0.39
SKP1 P63208 1/20 0.39
SKP2 Q13309 1/20 0.39
BTK Q06187 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20229515 0.89 PARP1 (0.42) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL17452537 0.86 PARP1 (0.41) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL19902296 0.80 JAK1 (0.49) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL19902293 0.80 JAK1 (0.49) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL19902295 0.80 JAK1 (0.49) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL17452540 0.79 PARP1 (0.41) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL17452520 0.75 ROCK2 (0.57) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL17452517 0.75 ROCK2 (0.57) PARP1KDM1AMAOBEPHX2JAK2
SCHEMBL30510784 0.71 PARP1 (0.48) PARP1KMT2ATNKSTNKS2
SCHEMBL29359692 0.71 CKS1B (0.41) KDM1AMAOBEPHX2JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 PARP1 1915/4885KDM1A 1333/4885MAOB 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.